Sei Investments Co. grew its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) by 60.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 336,562 shares of the pharmaceutical company’s stock after purchasing an additional 127,441 shares during the period. Sei Investments Co.’s holdings in GlaxoSmithKline PLC were worth $13,665,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in GSK. Renaissance Technologies LLC raised its holdings in shares of GlaxoSmithKline PLC by 112.1% during the second quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock valued at $402,655,000 after purchasing an additional 4,935,900 shares during the period. FMR LLC raised its holdings in shares of GlaxoSmithKline PLC by 5.9% during the second quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock valued at $1,079,047,000 after purchasing an additional 1,389,238 shares during the period. Federated Investors Inc. PA raised its holdings in shares of GlaxoSmithKline PLC by 22.7% during the second quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock valued at $194,521,000 after purchasing an additional 833,501 shares during the period. Marshall Wace North America L.P. raised its holdings in shares of GlaxoSmithKline PLC by 148.0% during the second quarter. Marshall Wace North America L.P. now owns 1,119,491 shares of the pharmaceutical company’s stock valued at $48,138,000 after purchasing an additional 668,088 shares during the period. Finally, Fisher Asset Management LLC raised its holdings in shares of GlaxoSmithKline PLC by 4.7% during the second quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock valued at $540,483,000 after purchasing an additional 564,519 shares during the period. Hedge funds and other institutional investors own 9.32% of the company’s stock.

In other news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the firm’s stock in a transaction on Monday, November 6th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 10.00% of the company’s stock.

WARNING: This report was posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/sei-investments-co-increases-stake-in-glaxosmithkline-plc-gsk/1711702.html.

GSK has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, July 21st. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Monday, July 24th. BidaskClub lowered shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. Citigroup Inc. restated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Thursday, July 27th. Finally, TheStreet lowered shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a report on Wednesday, July 26th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $44.33.

Shares of GlaxoSmithKline PLC (GSK) opened at $35.06 on Friday. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44. The company has a market cap of $85,410.00, a PE ratio of 12.40, a price-to-earnings-growth ratio of 1.94 and a beta of 1.00. GlaxoSmithKline PLC has a one year low of $34.72 and a one year high of $44.53.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Shareholders of record on Friday, November 10th will be paid a $0.5037 dividend. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $2.01 annualized dividend and a yield of 5.75%. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is 159.20%.

GlaxoSmithKline PLC Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.